2005
DOI: 10.1016/j.jcrs.2004.09.022
|View full text |Cite
|
Sign up to set email alerts
|

Masked comparison of silicone hydrogel lotrafilcon A and etafilcon A extended-wear bandage contact lenses after photorefractive keratectomy

Abstract: The lotrafilcon A lens resulted in significantly faster corneal reepithelialization and reduced patient discomfort in most patients during the first 48 hours after PRK.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
44
0
3

Year Published

2009
2009
2020
2020

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 64 publications
(47 citation statements)
references
References 5 publications
0
44
0
3
Order By: Relevance
“…Engle et al reported that corneal re-epithelialization after PRK was faster with less subjective complaints within the first 48 hours with lotrafilcon-A BCL compared to those with hydrogel BCL. 10 Our study identified that both groups using silicone hydrogel contact lenses had quickly completed re-epithelisation within the first 48 hours.…”
Section: 910mentioning
confidence: 76%
See 1 more Smart Citation
“…Engle et al reported that corneal re-epithelialization after PRK was faster with less subjective complaints within the first 48 hours with lotrafilcon-A BCL compared to those with hydrogel BCL. 10 Our study identified that both groups using silicone hydrogel contact lenses had quickly completed re-epithelisation within the first 48 hours.…”
Section: 910mentioning
confidence: 76%
“…Epithelial defect size was calculated by the equation A=π[(a+b)/4]², where the longest dimension of the defect was a and the shortest dimension of the defect was b. 10 While there was no epithelial defect observed, bandage contact lens was removed. Flourescein was instilled to confirm the absence of an epithelial defect.…”
Section: Surgical Techniquementioning
confidence: 99%
“…The diameter of epithelial removal was the same in all patients. The post PK remaining epithelial defect size (A) was calculated similar to other researchers [17] using the equation of A= π [(a+b)/4] 2.…”
Section: Discussionmentioning
confidence: 99%
“…However, the CL market is anything but small, with approximately 140 million current CL wearers worldwide that could benefit from using this technology, should the need arise for therapeutic intervention [49,50]. In addition, many spectacle wearers who undergo refractive surgery are able to wear a bandage lens for a short period of time [14,17,18,51], demonstrating the potential shortterm success of a therapeutic lens to treat disease. The higher cost of using a drug-delivering CL compared to eye drops may also be a barrier, thus putting the onus on the prescribing practitioner to be an advocate of the technology such that the virtues of the treatment strategy can be appropriately communicated.…”
Section: Acceptance -Can It Reach Clinicians and Affect Clinical Pracmentioning
confidence: 99%
“…Several commercially available CLs, including Pure Vision (balafilcon A, Bausch+Lomb), Acuvue 2 (etafilcon A, Vistakon Inc.), Acuvue Oasys (senofilcon A, Vistakon Inc.), and Air Optix Night & Day (lotrafilcon A, Alcon) are FDA approved for use as bandage lenses [13][14][15][16][17][18][19]. In most cases, antibiotics and anti-inflammatory drugs are administered in conjunction with the CLs by adding the medication topically over the lens in situ [13,20].…”
Section: Introductionmentioning
confidence: 99%